Company profile: Hycor Biomedical
1.1 - Company Overview
Company description
- Provider of diagnostic systems and assays for allergy and mast cell activation, including NOVEOS for allergy testing with small sample volumes; NOVEOS assay reagents, consumables, and supplies for specific IgE tests; a Tryptase Assay chemiluminescent microparticle immunoassay for serum tryptase detection; and TASSO+, a capillary blood collection device compatible with NOVEOS.
Products and services
- Tryptase Assay: A laboratory-grade chemiluminescent microparticle immunoassay detecting tryptase levels in human serum, indicating mast cell activation
- NOVEOS Assay Reagents, Consumables, and Supplies: A system-specific set of products used with NOVEOS for conducting specific IgE allergy tests, encompassing assay reagents, consumables, and supplies
- NOVEOS: A clinical-grade diagnostic system for allergy testing that uses a small sample size and reduces errors related to insufficient sample quantities, working with TASSO+ for less invasive collection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Hycor Biomedical
Vera Therapeutics
HQ: United States
Website
- Description: Provider of biologic therapeutics, including atacicept, a recombinant fusion protein containing the soluble TACI receptor that binds the cytokines BAFF and APRIL, used to treat IgA nephropathy and lupus nephritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vera Therapeutics company profile →
Equillium
HQ: United States
Website
- Description: Provider of therapeutics for autoimmune and inflammatory disorders, including itolizumab, a clinical-stage monoclonal antibody targeting the CD6-ALCAM pathway; EQ101, a tri-specific cytokine inhibitor of IL-2/IL-9/IL-15 in Phase 2 for alopecia areata; EQ302, an oral bi-specific inhibitor of IL-15/IL-21 in pre-clinical; and a multi-cytokine platform generating composite peptides to selectively block key cytokines at shared receptors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Equillium company profile →
Provention Bio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical solutions dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge approaches to intercept and prevent immune-mediated disease, using a predict-and-prevent model to intervene before disease onset.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Provention Bio company profile →
Epirus Biopharma
HQ: United States
Website
- Description: Provider of biosimilar monoclonal antibodies and therapeutic proteins for emerging markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epirus Biopharma company profile →
Medsenic
HQ: France
Website
- Description: Provider of drug development and manufacturing focused on drugs for the treatment of autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medsenic company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Hycor Biomedical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Hycor Biomedical
2.2 - Growth funds investing in similar companies to Hycor Biomedical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Hycor Biomedical
4.2 - Public trading comparable groups for Hycor Biomedical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →